TIDMPRTC
RNS Number : 0455P
PureTech Health PLC
15 June 2022
15 June 2022
PureTech Health plc
Results of Annual General Meeting
The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC,
LSE: PRTC) ("PureTech Health" or the "Company") was held at 11 a.m.
EDT/4 p.m. BST on Wednesday, June 15, 2022.
All of the resolutions proposed at the Annual General Meeting
were duly passed by the shareholders on a poll.
The results of the poll, incorporating the proxy votes lodged in
advance of the meeting, are set out below.
Resolutions For % Against % Withheld Total
votes
cast
001. To approve
the Company's
Annual Report
and Accounts for
year ended 31
December 2021 216,387,000 100.00 0 0.00 529,458 216,387,000
------------ ------- ----------- ------ --------- ------------
002. To approve
the Directors'
Remuneration Report 186,654,636 86.20 29,871,462 13.80 390,360 216,526,098
------------ ------- ----------- ------ --------- ------------
003. To elect
Ms. Sharon Barber-Lui
as a director 216,911,434 100.00 2,288 0.00 2,736 216,913,722
------------ ------- ----------- ------ --------- ------------
004. To elect
Dr. Raju Kucherlapati
as a director 214,260,532 98.78 2,653,190 1.22 2,736 216,913,722
------------ ------- ----------- ------ --------- ------------
005. To elect
Dr. John LaMattina
as a director 208,222,704 95.99 8,691,018 4.01 2,736 216,913,722
------------ ------- ----------- ------ --------- ------------
006. To elect
Ms. Kiran Mazumdar-Shaw
as a director 186,900,260 86.16 30,013,462 13.84 2,736 216,913,722
------------ ------- ----------- ------ --------- ------------
007. To elect
Dame Marjorie
Scardino as a
director 216,877,331 99.98 37,071 0.02 2,056 216,914,402
------------ ------- ----------- ------ --------- ------------
008. To elect
Mr. Christopher
Viehbacher as
a director 190,417,512 87.78 26,496,210 12.22 2,736 216,913,722
------------ ------- ----------- ------ --------- ------------
009. To elect
Dr. Robert Langer
as a director 212,747,748 98.08 4,165,974 1.92 2,736 216,913,722
------------ ------- ----------- ------ --------- ------------
010. To elect
Ms. Daphne Zohar
as a director 216,905,622 100.00 8,100 0.00 2,736 216,913,722
------------ ------- ----------- ------ --------- ------------
011. To elect
Dr. Bharatt Chowrira
as a director 216,706,444 99.90 207,278 0.10 2,736 216,913,722
------------ ------- ----------- ------ --------- ------------
012. To reappoint
KPMG LLP as Auditors
of the Company 212,180,052 97.82 4,729,435 2.18 6,971 216,909,487
------------ ------- ----------- ------ --------- ------------
013. To authorize
the Audit Committee
to determine the
Auditors' remuneration 212,703,757 98.06 4,211,701 1.94 1,000 216,915,458
------------ ------- ----------- ------ --------- ------------
014. To authorize
the allotment
of shares 212,364,212 97.90 4,551,246 2.10 1,000 216,915,458
------------ ------- ----------- ------ --------- ------------
015. To disapply
pre-emption rights 216,589,860 99.85 324,482 0.15 2,116 216,914,342
------------ ------- ----------- ------ --------- ------------
016. To further
disapply pre-emption
rights for acquisitions
and specified
capital investments. 204,225,243 94.15 12,689,099 5.85 2,116 216,914,342
------------ ------- ----------- ------ --------- ------------
017. To authorize
market purchase
of own shares 216,386,703 99.76 528,755 0.24 1,000 216,915,458
------------ ------- ----------- ------ --------- ------------
018. To authorize
general meetings
to be called on
not less than
14 clear days'
notice 212,326,728 97.88 4,588,730 2.12 1,000 216,915,458
------------ ------- ----------- ------ --------- ------------
Notes:
(1) A vote "Withheld" is not a vote in law and is not counted in
the calculation of the votes "For" or "Against" a resolution.
(2) As at June 13, 2022, the record date for the Annual General
Meeting, the number of issued shares in the Company entitling the
holders to attend and vote for or against all the resolutions at
the AGM was 287,633,591 ordinary shares. This does not include
977,529 shares held in treasury by the Company. In accordance with
the Company's Articles of Association, on a poll every member
present in person or by proxy has one vote for every share
held.
(3) The full text of the resolutions may be found in the Notice
of the Annual General Meeting, copies of which are available on
both the Company's website
https://investors.puretechhealth.com/financials-filings/reports and
on the National Storage Mechanism.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercializing highly
differentiated medicines for devastating diseases, including
inflammatory, fibrotic and immunological conditions, intractable
cancers, lymphatic and gastrointestinal diseases and neurological
and neuropsychological disorders, among others. The Company has
created a broad and deep pipeline through the expertise of its
experienced research and development team and its extensive network
of scientists, clinicians and industry leaders.
This pipeline, which is being advanced both internally and
through PureTech's Founded Entities, is comprised of 27
therapeutics and therapeutic candidates, including two that have
received both U.S. FDA clearance and European marketing
authorization, as of the date of PureTech's most recently filed
Annual Report and corresponding Form 6-K. All of the underlying
programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and
then advanced by the PureTech team through key validation points
based on unique insights in immunology and drug development.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this press release that do not relate to matters of historical
fact should be considered forward-looking statements, including
without limitation those related to our future prospects,
developments and strategies. The forward-looking statements are
based on current expectations and are subject to known and unknown
risks, uncertainties and other important factors that could cause
actual results, performance and achievements to differ materially
from current expectations, including, but not limited to, those
risks, uncertainties and other important factors described under
the caption "Risk Factors" in our Annual Report on Form 20-F for
the year ended December 31, 2021 filed with the SEC and in our
other regulatory filings. These forward-looking statements are
based on assumptions regarding the present and future business
strategies of the Company and the environment in which it will
operate in the future. Each forward-looking statement speaks only
as at the date of this press release. Except as required by law and
regulatory requirements, we disclaim any obligation to update or
revise these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
PureTech
Investor Relations
IR@puretechhealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGBKPBBABKDKAD
(END) Dow Jones Newswires
June 15, 2022 13:00 ET (17:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024
